Cargando…

Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis

INTRODUCTION: Tenofovir-containing regimens have demonstrated potential efficacy as pre-exposure prophylaxis (PrEP) in preventing HIV-1 infection. Transmitted drug resistance mutations associated with tenofovir, specifically the reverse transcriptase (RT) mutation K65R, may impact the effectiveness...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Philip A, Huang, Austin, Kantor, Rami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2012
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494163/ https://www.ncbi.nlm.nih.gov/pubmed/23305651 http://dx.doi.org/10.7448/IAS.15.2.17701

Ejemplares similares

Pre-Clinical Evaluation of Tenofovir and Tenofovir Alafenamide for HIV-1 Pre-Exposure Prophylaxis in Foreskin Tissue
por: Else, Laura, et al.
Publicado: (2022)

Comparing pharmacologic measures of tenofovir exposure in a U.S. pre-exposure prophylaxis randomized trial
por: Baxi, Sanjiv M., et al.
Publicado: (2018)

Acute Trigeminal Neuralgia Associated with Initiation of Emtricitabine/Tenofovir for HIV Pre-Exposure Prophylaxis
por: Van Slyke, Loraine, et al.
Publicado: (2018)

Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now
por: Mofenson, Lynne M.
Publicado: (2016)

Use of Tenofovir Alafenamide Fumarate for HIV Pre-Exposure Prophylaxis and Incidence of Hypertension and Initiation of Statins
por: Rivera, Adovich S., et al.
Publicado: (2023)

1551. Changes in Glomerular Filtration Rate after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis
por: Rivera, Adovich, et al.
Publicado: (2023)

The impact of HIV pre-exposure prophylaxis on sexually transmitted infections incidence in Bulgaria
por: Pakov, I, et al.
Publicado: (2023)

The Tenofovir Pre-Exposure Prophylaxis Trial in Thailand: Researchers Should Show More Openness in Their Engagement with the Community
por: Chua, Arlene, et al.
Publicado: (2005)

The Safety of Tenofovir–Emtricitabine for HIV Pre-Exposure Prophylaxis (PrEP) in Individuals With Active Hepatitis B
por: Solomon, Marc M., et al.
Publicado: (2016)

Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis
por: Baxter, Cheryl, et al.
Publicado: (2019)

Topical Tenofovir Pre-exposure Prophylaxis and Mucosal HIV-Specific Fc-Mediated Antibody Activities in Women
por: Fisher, Kimone Leigh, et al.
Publicado: (2020)

Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01
por: Huang, Yunda, et al.
Publicado: (2023)

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis
por: Solomon, Marc M., et al.
Publicado: (2014)

Tenofovir-Diphosphate as a Marker of HIV Pre-exposure Prophylaxis Use Among East African Men and Women
por: Pyra, Maria, et al.
Publicado: (2019)

Acute Weight Gain After Switch to Emtricitabine/Tenofovir Alafenamide for Human Immunodeficiency Virus Pre-Exposure Prophylaxis
por: Selvaraj, Shailendra V, et al.
Publicado: (2020)

Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis
por: Gunawardana, Manjula, et al.
Publicado: (2022)

1546. Relationship between Measured Glomerular Filtration Rate and Tenofovir Dried Blood Spot Concentrations among Transgender Adults on Tenofovir Alafenamide/Emtricitabine for Pre-Exposure Prophylaxis
por: Patel, Nimish, et al.
Publicado: (2023)

Is Emtricitabine-Tenofovir Disoproxil Fumarate Pre-exposure Prophylaxis for the Prevention of Human Immunodeficiency Virus Infection Safer Than Aspirin?
por: Kojima, Noah, et al.
Publicado: (2016)

Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP)
por: Li, Linying, et al.
Publicado: (2020)

853. Real-World Persistency of Patients Receiving Tenofovir-Based Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the US
por: Oglesby, Alan, et al.
Publicado: (2021)

Renal impairment associated with tenofovir disoproxil fumarate for antiretroviral therapy and HIV pre-exposure prophylaxis: An observational cohort study
por: Heron, Jack E., et al.
Publicado: (2023)

Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men
por: Mizushima, Daisuke, et al.
Publicado: (2023)

Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy
por: Scott, Rachel K., et al.
Publicado: (2023)

Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV
por: Devred, Inès, et al.
Publicado: (2023)

1495. Incidence of Sexually Transmitted Infections (STIs) in Patients on Pre-exposure Prophylaxis (PrEP)
por: Hamed, Almutase, et al.
Publicado: (2018)

Pre-exposure prophylaxis and bacterial sexually transmitted infections (STIs) among gay and bisexual men
por: Hart, Trevor A, et al.
Publicado: (2023)

Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial
por: Mandala, Justin, et al.
Publicado: (2014)

Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP)
por: Johnson, Leah M., et al.
Publicado: (2019)

Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users
por: Ayerdi, Oskar, et al.
Publicado: (2020)

Skating on thin ice: stimulant use and sub‐optimal adherence to HIV pre‐exposure prophylaxis
por: Hojilla, J Carlo, et al.
Publicado: (2018)

Assessing the need for a pre‐exposure prophylaxis programme using the social media app Grindr®
por: Hampel, B, et al.
Publicado: (2017)

Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial
por: Beesham, Ivana, et al.
Publicado: (2022)

Preferences for long‐acting pre‐exposure prophylaxis among gay, bisexual and other men who have sex with men in Taiwan: findings from the 2021 HEART Survey
por: Hsu, Jing‐Hao, et al.
Publicado: (2023)

High Prevalence of the K65R Mutation in HIV-1 Subtype C Infected Patients Failing Tenofovir-Based First-Line Regimens in South Africa
por: Skhosana, Lindiwe, et al.
Publicado: (2015)

Uptake and retention on HIV pre‐exposure prophylaxis among key and priority populations in South‐Central Uganda
por: Kagaayi, Joseph, et al.
Publicado: (2020)

High incidence of Hepatitis C virus infection observed in the PROUD study of HIV pre‐exposure prophylaxis
por: Desai, Monica, et al.
Publicado: (2020)

Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco
por: Liu, Albert Y., et al.
Publicado: (2011)

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients
por: Aloysius, Isaac, et al.
Publicado: (2017)

Daily HIV pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate-emtricitabine reduced Streptococcus and increased Erysipelotrichaceae in rectal microbiota
por: Dubé, Michael P., et al.
Publicado: (2018)

Tenofovir Disoproxil Fumarate-Associated Fanconi Syndrome in an Human Immunodeficiency Virus (HIV)-Uninfected Man Receiving HIV Pre-Exposure Prophylaxis
por: Khan, Soheb, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4re67jqvr9045glacegfim648r